Author: Ravi Shankar

Continued adoption of the QUELIMMUNE^® therapy yielded 247% increase in net revenue compared to the third quarter of 2025

Achieved nearly 75% enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with acute kidney injury (AKI) receiving CRRT

Reported statistically significant higher survival for QUELIMMUNE-treated patients versus comparator cohort at ASN Kidney Week 2026 late-breaking presentation

Fulfilled FDA post-approval requirements for SAVE Registry study

Webcast today at 4:30 p.m. Eastern Time

DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today financial results for the three months ended September 30, 2026, and provided business updates on key initiatives.

“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications,” said Eric Schlorff, CEO of SeaStar Medical. “And we continue to build momentum in educating the critical care pediatric health care community. In addition to several medical meeting presentations by Dr. Kevin Chung, our CMO, we have already begun sharing with critical care professionals the statistically significant higher survival in QUELIMMUNE-treated patients that was presented at the late-breaking presentation at ASN Kidney Week 2026.”

Mr. Schlorff continued, “The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval. Our Breakthrough Device Designation for this indication will also enable a priority review once we submit the final module with the NEUTRALIZE-AKI pivotal trial results, provided a positive outcome in the trial.”

Key Business Highlights

Since the beginning of the third quarter, SeaStar Medical’s key business updates include the following:

• Expanded the use of the QUELIMMUNE (SCD-PED) therapy as a treatment for ultra-rare sepsis-associated AKI in pediatric patients receiving renal replacement therapy (RRT), increasing net revenue 247% to $635 thousand compared to the third quarter of 2025. Gross profit margins remained at greater than 90%.
• Presented at ASN Kidney Week 2026 real-world pediatric patient survival data from the commercial use of the QUELIMMUNE therapy based on results from the SAVE Registry of 50 critically ill pediatric patients with life-threatening sepsis-associated AKI. The QUELIMMUNE (SCD-PED) therapy group showed statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discharge versus comparator cohorts. No device-related adverse events occurred in patients treated with the QUELIMMUNE (SCD-PED) therapy.
• Fulfilled FDA post-approval requirements for the SAVE Registry study for QUELIMMUNE for the treatment of sepsis-associated AKI in pediatric patients. FDA’s decision now enables hospitals to employ the QUELIMMUNE therapy without the research infrastructure that the SAVE Registry demanded, which may increase availability for these critically ill pediatric patients.
• Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial evaluating the SCD therapy as a potential treatment for adult patients with AKI in the ICU receiving continuous renal replacement therapy (CRRT). The trial is nearly 75% enrolled, with 251 of 339 patients enrolled to date. The NEUTRALIZE-AKI pivotal clinical trial is expected to complete enrollment by mid-year 2027.
• Completed and submitted to the FDA the first module of a modular premarket approval (PMA) application for the potential approval of the SCD therapy as a treatment for adult patients with AKI in the ICU receiving CRRT.
• Granted Breakthrough Device Designation from the FDA for the SCD therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic condition. The Breakthrough Device Designation is a regulatory pathway designed to provide for accelerated development, assessment, and review for FDA approval of medical devices and potentially more effective treatments of life-threatening or irreversibly debilitating diseases or conditions. This marks the seventh Breakthrough Device Designation for the SCD therapy thus far across a range of indications.
• Received dedicated International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS codes) from the Centers for Medicare & Medicaid Services (CMS). These codes, which took effect on October 1, 2026, enable administrative, billing, and statistical reporting for the use of SeaStar Medical’s SCD therapy in patients with AKI requiring RRT in the inpatient hospital setting.

Financial Results for the Third Quarter 2026

Net revenue for the three months ended September 30, 2026, and 2025, was approximately $0.6 million and $0.2 million, respectively, reflecting increased sales of QUELIMMUNE.

Cost of goods sold for the three months ended September 30, 2026, and 2025, was $48 thousand and $14 thousand respectively.

Research and development expenses for the three months ended September 30, 2026, and 2025, were $3.6 million and $1.9 million, respectively. The increase in research and development expenses was primarily driven by increased clinical research activities for the NEUTRALIZE-AKI pivotal clinical trial, SCD development costs, personnel, and payroll costs.

General and administrative expenses for the three months ended September 30, 2026, and 2025, were approximately $1.6 million and $1.9 million, respectively. The decrease in general and administrative expenses was the result of a decline in personnel, legal, audit, and SEC-related costs, partially offset by increased professional services, director fees, and franchise taxes.

Other income (net) for the three months ended September 30, 2026, was approximately $0.1 million compared to other expense of approximately $0.1 million for the three months ended September 30, 2025.

Net loss for the three months ended September 30, 2026, was approximately $4.5 million, or $1.03 per share on approximately 4.4 million weighted-average shares outstanding. This compares with a net loss of approximately $3.5 million, or $1.30 per share, on approximately 2.7 million weighted-average shares outstanding for the three months ended September 30, 2025.

Cash at September 30, 2026, was $4.0 million, which does not include the $3.3 million of gross proceeds from warrant exercises that occurred in October 2026. This compares to cash of $12.0 million at December 31, 2025.

SeaStar Medical Third Quarter Financial Results Conference Call

Date/Time:		Wednesday, November 11, 2026, at 4:30 p.m. ET / 2:30 p.m. MT
Webcast:		The live webcast and replay can be found here.
Register for the call:		Preregistration is required to attend the live call and can be accessed here. A pin code and dial in number will be provided with registration.

A replay of the call will be available after 7:30 p.m. ET and can be accessed here.

About QUELIMMUNE

The QUELIMMUNE^® (SCD-PED) therapy is being commercialized for children with AKI and sepsis or a septic condition weighing 10 kilograms or more and aged ≤22 years who are on antibiotics and being treated in the ICU with RRT. It was approved in February 2024 under a Humanitarian Device Exemption application.

Data from two clinical trials of the QUELIMMUNE therapy, published in Kidney Medicine, showed a 77% survival rate in patient treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data in this patient population. No dialysis was required for survivors, and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge.

The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy and could have broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.

QUELIMMUNE was approved by FDA under a Humanitarian Device Exemption based on safety and probable benefit.  The effectiveness of this device for this use has not been demonstrated. Adverse reactions observed in clinical studies include hypotension, hypothermia, tachycardia, hyperglycemia, and thrombocytopenia. Additional risks may include blood loss or extracorporeal circuit complications. QUELIMMUNE must be used with citrate anticoagulation.

For complete risk information, please see: https://seastarmedical.com/quelimmune 

About the SeaStar Medical Selective Cytopheretic Device (SCD) Therapy

The SCD therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy is designed for broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing CRRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future CRRT, including dialysis, and prevent loss of life.

About NEUTRALIZE-AKI Pivotal Trial

The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in AKI) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving CRRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to CRRT as the standard of care, compared with the control group receiving only CRRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome. 

About Acute Kidney Injury (AKI) and Hyperinflammation 

AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as severe infections or other septic conditions, severe trauma, surgery, and organ failures. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for seven therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to expanded access to critically ill pediatric patients as a result of the fulfillment of the SAVE Registry requirements, the potential benefit from the SCD-PED therapy with a favorable observed safety profile; anticipated improved survival in real-world critical care practice; anticipated adoption our products; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. 

Contact:  
IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.

— Financial Tables to Follow —

SeaStar Medical Holding Corporation Condensed Consolidated Balance Sheets (in thousands, except for share and per-share amounts)
		September 30, 2026				December 31, 2025
		(unaudited)
ASSETS
Current assets
Cash		$	3,989			$	11,980
Accounts receivable, net of allowance for credit losses of $2 and $3, respectively			178				237
Inventory			45				66
Prepaid expenses			755				1,297
Total current assets			4,967				13,580
Other assets			343				578
Total assets		$	5,310			$	14,158
LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)
Current liabilities
Accounts payable		$	1,467				948
Accrued expenses			3,373				2,268
Notes payable, net of deferred financing costs			—				525
Liability classified warrants			1				1
Total current liabilities			4,841				3,742
Total liabilities			4,841				3,742
Commitments and contingencies
Stockholders’ equity
Preferred stock – $0.0001 par value per share, 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025			—				—
Common stock – $0.0001 par value per share; 425,000,000 and 450,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 4,461,965 and 3,844,613 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively			4				4
Additional paid-in capital			163,959				162,126
Accumulated deficit			(163,494	)			(151,714	)
Total stockholders’ equity			469				10,416
Total liabilities and stockholders’ equity		$	5,310			$	14,158

SeaStar Medical Holding Corporation Condensed Consolidated Statements of Operations (unaudited) (in thousands, except for share and per-share amounts)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Net revenue		$	635			$	183			$	1,745			$	814
Cost of goods sold			48				14				148				41
Gross profit			587				169				1,597				773
Operating expenses
Research and development			3,574				1,850				8,438				5,318
General and administrative			1,594				1,898				5,134				4,614
Total operating expenses			5,168				3,748				13,572				9,932
Loss from operations			(4,581	)			(3,579	)			(11,975	)			(9,159	)
Other income (expense)
Interest income			54				107				214				200
Interest expense			(2	)			—				(16	)			(18	)
Other financing costs			—				—				—				(298	)
Change in fair value of warrants liability			—				—				—				32
Total other income (expense), net			52				107				198				(84	)
Loss before provision for income taxes			(4,529	)			(3,472	)			(11,777	)			(9,243	)
Provision for income taxes			—				—				3				3
Net loss		$	(4,529	)		$	(3,472	)		$	(11,780	)		$	(9,246	)
Net loss per share of common stock, basic and diluted		$	(1.03	)		$	(1.30	)		$	(2.85	)		$	(5.96	)
Weighted-average shares outstanding, basic and diluted			4,390,541				2,669,340				4,132,784				1,551,212

SeaStar Medical Holding Corporation Condensed Consolidated Statements of Cash Flows (unaudited)
		Nine Months Ended September 30,
		2026				2025
Cash flows from operating activities
Net loss		$	(11,780	)			(9,246	)
Adjustments to reconcile net loss to net cash used in operating activities			—				—
Amortization of deferred financing costs			16				18
Change in fair value of liability classified warrants			—				(32	)
Shares issued for the standby equity purchase agreement commitment fee			—				298
Stock-based compensation			155				554
Change in operating assets and liabilities
Accounts receivables, net			59				(109	)
Inventory			21				(83	)
Prepaid expenses			542				1,028
Other assets			235				236
Accounts payable			519				(1,028	)
Accrued expenses			1,105				(1,141	)
Net cash used in operating activities			(9,128	)			(9,505	)
Cash flows from financing activities
Proceeds from issuance of shares			1,678				14,337
Proceeds from exercise of warrants			—				1,818
Proceeds from issuance of pre-funded warrants			—				5,886
Payment of notes payable			(541	)			(592	)
Net cash provided by financing activities			1,137				21,449
Net increase in cash			(7,991	)			11,944
Cash, beginning of period			11,980				1,819
Cash, end of period		$	3,989			$	13,763

SAN FRANCISCO, Nov. 11, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that on November 10, 2026, its Board of Directors approved a share repurchase program with authorization to purchase up to $200 million of the company’s outstanding common stock.

The approval reflects iRhythm’s confidence in the continued strength of its core business, as well as its significant new growth opportunities from the addition of the recently acquired VitalConnect business.

Repurchases under the program may be made in the open market, in privately negotiated transactions, through accelerated share repurchase transactions or by other methods, with the amount and timing of repurchases to be determined at the company’s discretion, depending on market conditions and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal and state securities laws, including within the pricing and volume conditions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of its shares under this authorization. This program does not obligate the company to repurchase any particular dollar amount or number of shares of common stock and may be modified, suspended or terminated at any time at the discretion of its Board of Directors.

The company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.

About iRhythm Holdings, Inc.

iRhythm is a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. For more information, visit www.irhythmtech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include, without limitation, statements regarding the amount, timing, methods and sources of funding of repurchases under the share repurchase program and the structure of such repurchases, as well as statements regarding the continued strength of our core business and growth opportunities from the VitalConnect acquisition. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: risks relating to the fact that common stock repurchases may not be conducted in the timeframe or in the manner we expect, or at all; risks relating to our ability to successfully integrate the VitalConnect business and realize the anticipated benefits of the acquisition; intense competition in the markets we compete in; fluctuations in our operating results; future reimbursement and regulatory conditions; financial market conditions; the execution and effect of our business strategy; future business decisions made by us and our competitors; and additional risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 5, 2026. These forward-looking statements speak only as of the date of this press release and should not be unduly relied upon. We undertake no obligation to update them except as required by law.

Investor Contact
Francis Pruell
investors@irhythmtech.com

Media Contact
Kassandra Perry
mediarelations@irhythmtech.com

Tel-Aviv, Israel, Nov. 11, 2026 (GLOBE NEWSWIRE) — Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and USA, today announced that it will hold its annual general meeting of shareholders (the “Meeting”) at the Company’s offices at 18 Rothschild Boulevard, 1st Floor, Tel Aviv 6688121, Israel, on Wednesday, December 16, 2026, at 3:00 p.m., Israel time, and thereafter as it may be adjourned or postponed from time to time.

The agenda of the Meeting will be as follows:

1.      Reelection of Ben Sheizaf, Ran Fridrich, Odelya Ohayon and Gilad Mamlok as directors;

2.      Reelection of Daniel Vaknin as an external director for a third three-year term;

3.      Reelection of Dorit Ben Simon as an external director for a second three-year term;

4.      Approval of the terms of service of the external directors;

5.      Approval of grant of options to the external directors;

6.      Approval of an updated compensation policy for the Company’s officers and directors;

7.      Reappointment of Somekh Chaikin, a member of KPMG International, as the independent auditors of the Company for the fiscal year ending December 31, 2026 and until the next annual general meeting of the Company’s shareholders, and authorization of the Board of Directors of the Company to set their remuneration in accordance with the volume and nature of their services, or to delegate such power to the Audit Committee; and

8.      Receipt and consideration of the Auditors’ Report and the Financial Statements of the Company for the fiscal year ended December 31, 2025.  

Shareholders of record as of the close of business on November 16, 2026 will be entitled to vote at the Meeting or any adjournments or postponements thereof. The Company plans to mail a proxy statement that describes the proposals to be considered at the Meeting and a proxy card on or about November 17, 2026. A proxy statement and proxy card will also be furnished to the Securities and Exchange Commission on Form 6-K on or about November 12, 2026.

Each of the resolutions to be presented at the Meeting requires the affirmative vote of holders of at least a majority of the ordinary shares voted at the Meeting on the matter presented for passage, in person or by proxy or via the electronic system of the Israel Securities Authority. The approval of the proposals under Item 2, 3, 5 and 6 is also required to comply with additional special “disinterested” voting requirements as set forth in the proxy statement. Item 8 does not require a shareholder vote.

Eligible shareholders may present proper proposals for inclusion in the Meeting by submitting their proposals to the Company no later than November 18, 2026.

Shareholders may vote their ordinary shares by means of a proxy card, which is required to be received by the Company, along with the documentation set forth in the proxy statement, by 11:00 a.m., Israel time, on December 16, 2026 (four hours prior to the Meeting), to be counted for the Meeting, or through the electronic system of the Israel Securities Authority until six hours prior to the Meeting.

About Ellomay Capital Ltd.

Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol “ELLO”. Since 2009, Ellomay focuses its business in the renewable energy and power sectors in Europe, USA and Israel.

To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in Israel, Italy, Spain, the Netherlands and USA, including:

• Approximately 335.9 MW of operating solar power plants in Spain (including a 300 MW solar plant in owned by Talasol, which is 51% owned by the Company) and 51% of approximately 143 MW of operating solar power plants in Italy;
   
• Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the Netherlands, with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million Nm3 per year, respectively;
   
• 83.333% of Ellomay Pumped Storage (2014) Ltd., which is involved in a project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel;
   
• 51% of solar projects in Italy with an aggregate capacity of approximately 55 MW that are under construction;
   
• Solar projects in Italy with an aggregate capacity of approximately 227 MW that have reached “ready to build” status; and
   
• Solar projects in the Dallas Metropolitan area, Texas, USA with an aggregate capacity of approximately 49 MW that are connected to the grid and 14 MW that is awaiting connection to the grid.

For more information about Ellomay, visit http://www.ellomay.com.

Information Relating to Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words “estimate,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company’s forward-looking statements, including changes in electricity prices and demand, regulatory changes increases in interest rates and inflation, changes in the supply and prices of resources required for the operation of the Company’s facilities (such as waste and natural gas) and in the price of oil, the impact of the war and hostilities in Israel and Gaza and between Israel and Iran, the impact of the continued military conflict between Russia and Ukraine, technical and other disruptions in the operations or construction of the power plants owned by the Company, inability to obtain the financing required for the development and construction of projects, increases in interest rates and inflation, changes in exchange rates, delays in development, construction, or commencement of operation of the projects under development, failure to obtain permits – whether within the set time frame or at all, climate change, and general market, political and economic conditions in the countries in which the Company operates, including Israel, Spain, Italy and the United States. These and other risks and uncertainties associated with the Company’s business are described in greater detail in the filings the Company makes from time to time with the Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Kalia Rubenbach (Weintraub)
CFO
Tel: +972 (3) 797-1111
Email: hilai@ellomay.com

HAMILTON, Bermuda, Nov. 11, 2026 (GLOBE NEWSWIRE) — Teekay Tankers Ltd. (Teekay Tankers or the Company) (NYSE: TNK) today reported the Company’s results for the three months ended September 30, 2026 and announced that its Board of Directors has declared its fixed quarterly cash dividend of $0.25 per share for the quarter ended September 30, 2026. The cash dividend is payable on December 4, 2026 to all shareholders of record as at November 23, 2026.

The full earnings release and Teekay Group’s earnings presentation are available on the Company’s website here.

About Teekay Tankers

Teekay Tankers has a fleet of 38 double-hulled crude oil and product tankers (which includes committed newbuildings) and three time chartered-in oil and product tankers. Teekay Tankers’ vessels are typically employed through a mix of spot tanker market trading and short- or medium-term fixed-rate time charter contracts. In addition, Teekay Tankers manages and operates vessels for the Australian government and Australian energy companies as part of the marine services provided by the Company and owns a ship-to-ship transfer business that performs full service lightering and lightering support operations in the U.S. Gulf and Caribbean. Teekay Tankers was formed in December 2007 by Teekay Corporation Ltd.

Teekay Tankers’ Class A common shares trade on the New York Stock Exchange under the symbol “TNK.”

For Investor Relations enquiries contact:

E-mail: investor.relations@teekay.com
Website: www.teekay.com

Earnings Release: Monday, November 30, 2026, Before Market Opens 

Conference Call and Webcast: Monday, November 30, 2026, at 09:00 A.M. Eastern Time

ATHENS, Greece and NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) — Heidmar Maritime Holdings Corp. (the “Company” or “Heidmar”) (NASDAQ: HMR), today announces that it will release its results for the third quarter ended September 30, 2026, before market opens on Monday, November 30, 2026. Heidmar’s management team will host a conference call to discuss the Company’s financial results on Monday, November 30, 2026, at 09:00 a.m. Eastern Time (ET).

Conference Call details:

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: +1 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In), or +0 800 756 3429 (UK Toll Free Dial In). Please quote “Heidmar” to the operator and/or conference ID 13763844. Click here for additional participant International Toll-Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Webcast:

There will also be a live, and then archived, webcast of the conference call, available through the Company’s website. To listen to the archived audio file, visit www.heidmar.com and click on Financials & Presentations. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

About Heidmar, Inc.

Heidmar is an Athens based, commercial and pool management business servicing the crude and product tanker market and is committed to safety, performance, relationships and transparency. With operations in Athens, London, Singapore, Chennai, and Hong Kong, Heidmar has a reputation as a reliable and responsible partner with a goal of maximizing our customers’ profitability. Heidmar seeks to offer vessel owners a “one-stop” solution for all maritime services in the crude oil, refined petroleum products and dry bulk shipping sectors. Heidmar believes its unique business model and extensive experience in the maritime industry allows the Company to achieve premier market coverage and utilization, as well as provide customers in the sector with seamless commercial transportation services. For more information, please visit www.heidmar.com.

CONTACT INFORMATION:

Investor Relations/Media Contact:

Nicolas Bornozis / Daniela Guerrero
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, N.Y. 10169
Tel.: (212) 661-7566
Email: heidmar@capitallink.com

Top-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani’s miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated for announcement later this week

Cortigent-ClearOne merger is awaiting final regulatory approvals allowing establishment of Cortigent as a standalone company trading on the Nasdaq under ticker symbol CRGT

ALAMEDA, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

“The third quarter and recent weeks mark a period of strong progress and forward momentum for Vivani” said Adam Mendelsohn, PhD, CEO of the Company. “The top-line SLIM-1 results will be announced this week. We look forward to sharing those results with shareholders, industry peers, and the broader community of physicians and patients seeking less frequent dosing and the promise of potential improvements in convenience, medication adherence, and tolerability associated with GLP-1 therapies on the market and in clinical-stage development.”

Dr. Mendelsohn continued: “Roughly half of patients don’t take their medications for chronic diseases as prescribed, and GLP-1 therapies are no exception. With NPM-139, we are designing a novel GLP-1 therapy that a patient could receive once or twice a year during a routine primary care visit. Another key feature afforded by our unique NanoPortal implant technology is the ability to provide an “off-ramp” when discontinuation of therapy is warranted for example when a woman becomes pregnant or there is an aspiration risk during surgery. While there are multiple GLP-1 injectable candidates targeting monthly or quarterly administration under development, none can offer reversibility comparable to our NanoPortal implants. We strongly believe this could be an important consideration for the more than 20% of current GLP-1 users who are women of child-bearing potential.”

Recent Business Highlights

On October 30, 2026, the Company filed an current report on Form 8-K with the U.S. Securities and Exchange Commission to clarify that the expected close of the of the Cortigent merger remains subject to final regulatory approval and is expected to close shortly after approval is received.

On August 6, 2026, Vivani announced full enrollment and successful initial dosing of all participants in its SLIM-1™ Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant being designed to provide six- to twelve-months of continuous drug delivery utilizing our proprietary NanoPortal™ technology. The trial of 20 GLP-1 naïve participants in Australia includes low-doses of NPM-139 and Wegovy® to assess safety, tolerability, and pharmacokinetics. Changes in weight were measured. Top-Line results from the SLIM-1 trial are anticipated to be announced later this week.   

On July 7, 2026, the Company announced the signing of a new agreement with Novo Nordisk, now known as Novo, to evaluate NPM-139, the Company’s semaglutide drug implant. NPM-139 is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani’s proprietary NanoPortal technology associated with this agreement.

On July 2, 2026, Vivani announced that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly owned subsidiary Cortigent Inc., ClearOne, Inc., a Nasdaq-listed company, and a wholly owned subsidiary of ClearOne (“MergerSub”), pursuant to which Cortigent will become a wholly owned subsidiary of ClearOne upon consummation. In connection with the transaction, ClearOne is pursuing a financing which aims to raise $10 million to $15 million concurrently with the merger’s closing.

Upcoming Anticipated Milestones

Release of top-line data for SLIM-1, the on-going Phase 1 study of low-dose NPM-139, Vivani’s miniature, ultra long-acting semaglutide implant under development for chronic weight management, are anticipated in November 2026.

Preparation, and submission of an Investigational New Drug (“IND”) Application for NPM-139 to support initiation of a proposed Phase 2 dose-ranging study of this semaglutide implant is planned for 2027.

The transition of Cortigent into an independent, publicly traded company shortly after receiving final regulatory approval and completion of all closing and related financing activities.

Third Quarter 2026 Financial Results
Cash: As of September 30, 2026, Vivani had cash, cash equivalents and restricted cash totaling $15.5 million, compared to $20.8 million as of June 30, 2026.

Research and development expense, net: Research and development expense, net of grants, during the three months ended September 30, 2026 was $5.0 million, compared to $4.5 million during the three months ended September 30, 2025. The increase of $0.5 million, or 11%, was primarily attributable to an increase in the clinical trial related expense from our Biopharm Division.

General and administrative expense, net: General and administrative expense, net of grants, during the three months ended September 30, 2026 was $2.5 million, compared to $2.2 million during the three months ended September 30, 2025. The increase of $0.3 million, or 14%, was primarily attributable to an increase in personnel and related expenses from our Neurostimulation Division and our Biopharm Division.

Other income, net: Other income, net during the three months ended September 30, 2026 was $0.3 million, compared to $0.2 million during the three months ended September 30, 2025. The increase of $0.1 million was primarily attributable to amounts recognized under the Australian R&D Tax Incentive Program and higher interest income earned during the period.

Net loss: For the foregoing reasons, we had a net loss of $7.3 million during the three months ended September 30, 2026 compared to $6.5 million during the three months ended September 30, 2025.

About SLIM-1™ Trial

SLIM-1 is an open-label, active-controlled trial evaluating a low-dose NPM-139 (semaglutide implant) given to 10 participants, and the starting dose of Wegovy (0.25mg/week semaglutide injection) given to 10 participants, over a four-week duration. The trial was designed to evaluate the safety, tolerability and pharmacokinetic profile in overweight or obese participants who are otherwise healthy. Changes in weight were also measured. Top-line results from SLIM-1 are anticipated to be released later this week.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com.

About Cortigent, Inc.

Cortigent, Inc., a wholly owned subsidiary of Vivani, is developing brain implant devices to help patients recover critical body functions. Its patent-protected precision neurostimulation technology platform leverages neuroscience and proprietary microelectronics to create advanced medical devices. Vivani’s predecessor, Second Sight Medical Products, previously marketed Argus® II, the first and only medical device to obtain FDA approval to treat a rare form of blindness. This innovative device has helped hundreds of profoundly blind patients to achieve meaningful visual perception. Cortigent’s next generation investigational system, the Orion® cortical stimulation system, has been designed to treat blindness caused by common conditions including glaucoma and diabetic retinopathy. Orion has an FDA Breakthrough Device designation, completed a 6-year Early Feasibility Study in 2025 with promising safety and efficacy results and is covered by an extensive intellectual property estate. Cortigent is also applying its core technology to improving recovery of arm and hand motion in patients with paralysis due to stroke. For more information and patient videos, please visit: www.cortigent.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential or the planned development thereof, and its technology, strategy, cash position and financial runway, and the closing of the Cortigent merger. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays, and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani’s expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (the “SEC”) including the factors described in Vivani’s most recent Quarterly Report on Form 10-Q filed with the SEC on August 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462

Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462

VIVANI MEDICAL, INC.
AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(In thousands, except per share data)
	September 30,				December 31,
	2026				2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	14,591			$	16,232
R&D tax credit incentive receivable		305				654
Prepaid expenses and other current assets		937				1,012
Total current assets		15,833				17,898
Property and equipment, net		2,763				2,879
Operating lease right-of-use assets, net		15,713				17,230
Restricted cash		892				1,338
Deposits and other assets		109				48
TOTAL ASSETS	$	35,310			$	39,393
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	1,210			$	1,032
Accrued expenses		1,361				1,736
Litigation accrual		1,790				1,675
Accrued compensation expense		319				365
Lease liability, current portion		1,905				1,794
Total current liabilities		6,585				6,602
Lease liability, noncurrent portion		15,507				17,061
TOTAL LIABILITIES		22,092				23,663
Commitments and contingencies (Note 12)
STOCKHOLDERS’ EQUITY:
Common stock, par value $0.0001 per share; 300,000 shares authorized; shares issued and outstanding: 90,300 and 76,428 at September 30, 2026 and December 31, 2025, respectively		9				8
Additional paid-in capital		182,110				164,225
Accumulated other comprehensive income		32				30
Accumulated deficit		(168,933	)			(148,533	)
TOTAL STOCKHOLDERS’ EQUITY		13,218				15,730
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	35,310			$	39,393

VIVANI MEDICAL, INC.
AND SUBSIDIARIES
Condensed Consolidated Statements of Operations (Unaudited)
(In thousands, except per share data)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Operating expenses:
Research and development	$	5,021			$	4,519			$	13,978			$	13,496
General and administrative		2,511				2,206				7,375				7,250
Total operating expenses		7,532				6,725				21,353				20,746
Loss from operations		(7,532	)			(6,725	)			(21,353	)			(20,746	)
Other income, net		282				195				953				770
Net loss	$	(7,250	)		$	(6,530	)		$	(20,400	)		$	(19,976	)
Net loss per common share – basic and diluted	$	(0.08	)		$	(0.11	)		$	(0.24	)		$	(0.34	)
Weighted average shares outstanding – basic and diluted		90,119				59,711				86,192				59,399

Pelareorep and toripalimab combine potentially complementary mechanisms designed to enhance antitumor immune responses and help overcome tumor immune resistance

Study may represent a first step toward evaluating the combination more broadly across HPV-associated cancers

SAN DIEGO, Nov. 11, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech^® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, announced today that it has entered into a clinical supply agreement with Coherus Oncology, Inc. (“Coherus”) to evaluate Oncolytics’ investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus’ next-generation PD-1 inhibitor, LOQTORZI^® (toripalimab-tpzi), in a clinical study in patients with squamous cell anal carcinoma (“SCAC”).

The study is expected to be conducted at a premier cancer center in the United States, which will be named once the study commences, and is anticipated to begin in the first quarter of 2027. It is expected to enroll patients who have progressed on the current standard-of-care first-line treatment of chemotherapy and checkpoint inhibition. Importantly, there is no approved therapy for second-line patients in this indication.

Under the terms of the clinical supply agreement, Coherus will provide LOQTORZI^® to Oncolytics, which is expected to partner with the institution sponsoring the planned clinical study.

“This agreement supports a focused clinical evaluation of pelareorep with a marketed PD-1 inhibitor in a difficult-to-treat patient population,” said Jared Kelly, Chief Executive Officer of Oncolytics. “The planned study is designed to build upon the previous efficacy signals pelareorep has shown in second-line or later SCAC patients while getting data in a patient population that has progressed on the new first-line standard of care. If the results are supportive, we believe SCAC could provide an important first step toward evaluating this combination more broadly across HPV-associated cancers.”

Rationale for the Pelareorep and Toripalimab Combination

Pelareorep is designed to activate toll-like receptor 3, stimulating innate and adaptive antitumor immune responses, and to promote the formation of tertiary lymphoid structures within the tumor, which have been associated with improved responses to checkpoint inhibitor therapy. Through these mechanisms, pelareorep promotes tumor-directed T-cell activation and infiltration and induces inflammatory signaling within the tumor microenvironment. Recent translational data presented at the Society for Immunotherapy of Cancer Annual Meeting showed that pelareorep combined with a checkpoint inhibitor increases human papillomavirus (“HPV”)-16-specific T cell clones and tumor-infiltrating lymphocyte clones in SCAC patients. Toripalimab blocks the PD-1 pathway, a mechanism tumors can use to suppress activated T cells. The planned study will evaluate whether pelareorep-mediated immune activation can enhance the antitumor activity of PD-1 blockade in SCAC patients who have progressed on chemo-immunotherapy treatment.

SCAC is an HPV-associated cancer with limited treatment options for patients whose disease progresses after available therapy. Because HPV-associated tumors express viral antigens that may provide recognizable immune targets, the SCAC study may also inform a potential broader development strategy across HPV-associated cancers.

About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

About Toripalimab
LOQTORZI^® (toripalimab-tpzi) is a next-generation PD-1 inhibitor and is the only available FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma. It is also being developed for additional tumor types with the goal of serving as a PD-1 inhibitor backbone for future treatment combinations that may extend survival for patients.

About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically inactive tumors to active through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.

Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding the Company’s beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the plans for, and the market opportunity and potential effects of, the collaboration agreement with Coherus; the plans and timeline for building on previous SCAC data; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies; the Company’s belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers; and plans for future disclosure of clinical trial results. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.

Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.com

HOUSTON, Nov. 11, 2026 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN; NYSE TX: ORN) (“Orion” or the “Company”), a leading specialty construction company, today announced the appointment of United States Navy Rear Admiral (Ret.) Mark A. Handley to its Board of Directors effective November 11, 2026.

Mr. Handley brings a track record of driving growth, backed by extensive experience in delivery of large-scale infrastructure, government procurement, risk management, and strategic corporate governance. His background includes senior leadership roles at AECOM (NYSE: ACM) and 32 years in the U.S. Navy Civil Engineer Corps.

“We are pleased to welcome Mark to our Board,” said Austin Shanfelter, Chairman of the Board of Orion. “Mark’s deep understanding of how Naval and federal customers plan, prioritize and deliver projects, combined with his strength in setting and executing strategy in a global Fortune 500 company are invaluable as we pursue the significant marine opportunities ahead and create value for our shareholders. As a retired Naval officer, it is especially fitting to welcome Mark on Veterans Day.”

Mr. Handley commented, “Having spent my career building and maintaining the critical infrastructure our Naval forces depend on, I have great respect for the important work Orion does. I am excited to join the Board and look forward to contributing to the Company’s continued success.”

Mr. Handley is 67 years of age and has more than 40 years of leadership experience in military and private-sector infrastructure. He held various senior leadership roles at AECOM. As Senior Vice President, Strategy and Growth Leader of Federal Programs, Mr. Handley led strategy for the federal business that delivered consistent year-over-year double-digit growth and supported over $1.5 billion of architecture, engineering, and construction contracts annually.

Over the course of a 32-year career in the Navy, Mr. Handley’s leadership assignments included Commander of the First Naval Construction Division (Seabees), leading 16,500 personnel executing global construction; Director of Shore Readiness for the Office of the Chief of Naval Operations, overseeing $9 billion in annual infrastructure expenditures; Resident Officer in Charge of Construction Mid-Pacific in Pearl Harbor, HI; and Commanding Officer of NAVFAC Mid-Atlantic in Norfolk, VA.

Mr. Handley serves on the board of two leading private infrastructure and construction firms, advising on Audit, Finance, Ethics, and Governance committees. He also serves as First Vice Chair of the National Academy of Construction and as Governance Chair for the Society of American Military Engineers (SAME) Foundation. He previously served as National President of SAME.

Mr. Handley holds a Bachelor of Mechanical Engineering degree from Villanova University, a Master of Science in Engineering degree specializing in Construction Management from Stanford University and completed the Executive Management Program at the University of Michigan Ross School of Business.

The appointment of Mr. Handley to the Board of Directors is effective November 11, 2026, and he will be eligible for election at the 2027 annual general meeting of stockholders. With the appointment of Mr. Handley, the Orion Board of Directors will expand to seven Directors.

Orion’s Commitment to Veterans

This appointment coincides with Veterans Day and reflects Orion’s broader commitment to those who have served. Through Task Force Vets, a group of Orion leaders focused on veteran recruitment and outreach, and our VALOR veteran employee resource group, Orion helps veterans transition into civilian careers and grow within Orion. Orion also partners with the Department of Veterans Affairs, the Department of War, and military career fairs to connect veterans with opportunities across Orion. Today, veterans contribute at every level of Orion, from field operations and project management to senior leadership, including United States Navy Captain (Ret.) James “Gordie” Meyer who last served as Vice Commander NAVFAC Pacific and currently serves as our Vice President, Hawaii Pacific Operations based in Honolulu, HI, and United States Navy Captain (Ret.) Lance Flood who last served as Chief of Staff for the Navy Expeditionary Combat Command and currently serves as our Director of Atlantic and Federal Programs based in Norfolk, VA.

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including place and finish, site prep, layout, forming, and rebar placement for large commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas with regional offices throughout its operating areas. https://www.oriongroupholdingsinc.com.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the “safe harbor” provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, of which provisions the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as “believes,” “expects,” “may,” “will,” “could,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” or “anticipates,” or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, guidance, outlook, assumptions, or goals. In particular, statements regarding our pipeline of opportunities, achievement of strategic priorities, position for growth, financial guidance and future operations or results, including those set forth in this press release, and any other statement, express or implied, concerning financial guidance or future operating results or the future generation of or ability to generate revenues, income, net income, gross profit, EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, or cash flow, including to service debt or maintain compliance with debt covenants, and including any estimates, guidance, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward-looking statements also include project award announcements, estimated project start dates, ramp-up of contract activity and exercise of contract options, which may or may not be awarded in the future. Forward-looking statements involve risks, including those associated with the Company’s fixed price contracts that impact profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints, and any potential contract options that may or may not be awarded in the future, and are at the sole discretion of award by the customer, integration risk, availability of liquidity, labor availability, labor-cost inflation, subcontractor performance, equipment availability, and supply-chain disruptions. Past performance is not necessarily an indicator of future results. Considering these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise, except as required by law.

Please refer to the Company’s 2025 Annual Report on Form 10-K, filed on March 4, 2026, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, and filings and press releases subsequent to such Annual Report on Form 10-K for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Contact:

Margaret Boyce
Orion Group Holdings, Inc.
Mboyce@orn.net
346-278-3762

Source: Orion Group Holdings, Inc.

Revenues Up 26% and Operating Cash Flow Per Share Up 21%, Year-Over-Year

On Track to Achieve 2026 GEO Guidance; Windfall Project Receives Québec Environmental Approval

MONTRÉAL, Nov. 11, 2026 (GLOBE NEWSWIRE) — OR Royalties Inc. (“OR Royalties” or the “Company“) (OR: TSX & NYSE) today announced strong consolidated financial results for the third quarter of 2026 (“Q3 2026¹“). Revenues of $90.2 million and cash flows from operating activities of $77.6 million increased 26% and 20%, respectively, over the third quarter of 2025 (“Q3 2025¹“) on a comparable 20,237 gold equivalent ounces² (“GEOs”) earned, as the Company’s 96.8% cash margin³ converted higher precious metals prices almost entirely into cash. With 63,734 GEOs earned over the first nine months of 2026, OR Royalties remains on track for approximately the mid-point of its 2026 guidance of 80,000 to 90,000 GEOs. Amounts are presented in United States dollars unless otherwise noted.

Third Quarter 2026 Highlights (compared to Q3 2025)

• Revenues of $90.2 million, up 26% ($71.6 million) on 20,237 GEOs earned (20,326 GEOs);
• Cash flows from operating activities of $77.6 million, or $0.42 per basic share³, up 21% per basic share ($64.6 million, or $0.34 per basic share);
• Cash margin of $87.3 million, or 96.8% of revenues, up 26% ($69.3 million, or 96.7%);
• Net earnings of $55.4 million, or $0.30 per basic share, down 33% ($82.8 million, or $0.44 per basic share; Q3 2025 included a $54.4 million non-cash gain on the deemed disposal of an associate);
• Adjusted earnings³ of $53.9 million, or $0.29 per basic share, up 28% ($42.3 million, or $0.22 per basic share);
• Record nine-month revenues of $290.9 million (up 56%), cash flows from operating activities of $232.6 million, or $1.24 per basic share (up 44%), cash margin of $281.5 million (up 56%), net earnings of $190.3 million, or $1.02 per basic share (up 35%), and adjusted earnings of $189.5 million, or $1.01 per basic share (up 79%);
• 63,734 GEOs earned in the first nine months of 2026 (up 8%), tracking to approximately the mid-point of the Company’s previously published 2026 guidance range of 80,000 to 90,000 GEOs;
• Closing of $43.0 million from previously announced acquisitions: the Canadian Copper Inc. precious metals stream on the Murray Brook and Caribou assets ($28.0 million) and the extension of the Costa Fuego royalties to Hot Chili Limited’s La Verde project ($15.0 million);
• Three new mines in the portfolio entered production in 2026: Ramelius Resources Limited’s Dalgaranga (first royalty payment received in April 2026), Cabral Gold Inc.’s Cuiú Cuiú (first gold pour September 10, 2026) and United Gold’s Amulsar (first gold pour October 10, 2026);
• Repurchase and cancellation of 1,007,496 common shares for $29.1 million (C$40.8 million) under the normal course issuer bid, bringing 2026 repurchases to 1,555,678 common shares;
• Revolving credit facility increased to $850.0 million from $650.0 million, uncommitted accordion increased to $350.0 million from $200.0 million, and maturity extended to August 4, 2030;
• Cash of $76.7 million and debt of $228.2 million at September 30, 2026, for a net debt position³ of $151.5 million and available liquidity⁴ of approximately $1.0 billion; and,
• Declaration of the 48^th consecutive quarterly dividend of $0.065 per common share paid on October 15, 2026 to shareholders of record on September 30, 2026.

Summary of Results

(in thousands of dollars, except GEOs and per share amounts)	Q3 2026		Q3 2025		Change		9M 2026		9M 2025		Change
GEOs earned	20,237		20,326		(0.4%)		63,734		59,040		8%
Revenues	90,205		71,625		26%		290,857		186,905		56%
Cash flows from operating activities	77,564		64,604		20%		232,596		162,058		44%
per basic share	0.42		0.34		21%		1.24		0.86		44%
Cash margin (in dollars)	87,288		69,258		26%		281,508		180,359		56%
Cash margin (% of revenues)	96.8%		96.7%				96.8%		96.5%
Net earnings5	55,367		82,845		(33%)		190,341		140,843		35%
per basic share	0.30		0.44		(33%)		1.02		0.75		35%
Adjusted earnings	53,940		42,267		28%		189,464		105,879		79%
per basic share	0.29		0.22		29%		1.01		0.56		79%
Realized gold price (LBMA PM, $/oz)	4,304		3,434		25%		4,559		3,188		43%

Subsequent to September 30, 2026

• Windfall environmental approval. On November 2, 2026, Gold Fields Limited (“Gold Fields”) announced that the Québec Ministry of Environment, Fight Against Climate Change, Wildlife and Parks issued the certificate of authorization required to begin construction of the Windfall project. Gold Fields expects to publish its Final Investment Decision by February 2027; Windfall is expected to produce approximately 300,000 ounces of gold per year once ramped up. OR Royalties holds a 2.0% to 3.0% net smelter return (“NSR”) royalty on Windfall;
• Amulsar first gold. On October 10, 2026, United Gold announced first gold production at the Amulsar heap-leach gold mine in Armenia, on which OR Royalties International Ltd. holds gold and silver streams;
• Cascabel NSR royalty partial buy-back. The Company received notice from SolGold Finance AG of its intention to exercise its option to buy back one-third of the Company’s NSR royalty on the Cascabel project for cash consideration of $35.0 million, expected to be effective on November 30, 2026. Following the buy-back, the Company will retain a 0.4% NSR royalty on Cascabel;
• Galiano Gold Inc. deferred payment. The first of two deferred payments of $30.0 million acquired as part of the Gold Fields portfolio acquisition announced in February 2026 is due from Galiano Gold Inc. on or before December 31, 2026. Together with the Cascabel buy-back, approximately $65.0 million of cash inflows are expected in the fourth quarter of 2026 in addition to operating cash flows;
• Japan Gold Corp. On November 4, 2026, the Company closed the previously announced exercise of its right to increase its NSR royalty on all properties being advanced by Japan Gold Corp. by 0.5% to 2.0%, for $3.0 million;
• Eagle mine. On October 22, 2026, Boroo Pte. Ltd. announced an agreement to acquire Victoria Gold Corp., owner of the Eagle gold mine in Yukon, from the court-appointed receiver, with closing targeted on or about December 31, 2026, subject to court approval and other conditions. OR Royalties holds a 5.0% NSR royalty on Eagle, which has been on care and maintenance since mid-2024; and,
• Declaration of a quarterly dividend of $0.065 per common share payable on January 15, 2027 to shareholders of record as of the close of business on December 31, 2026.

Portfolio Additions

During the quarter, OR Royalties closed the $28.0 million precious metals stream with Canadian Copper Inc. on its New Brunswick assets, comprising the Murray Brook properties and the Caribou property, including the Caribou Processing Plant ($5.0 million paid on closing), together with a $3.9 million (C$5.5 million) equity purchase in Canadian Copper, and the $15.0 million extension of the Company’s 1.0% copper and 3.0% NSR gold royalties on Hot Chili Limited’s Costa Fuego project to the adjacent La Verde project in Chile. In September, the Company exercised its $3.0 million option to increase its NSR royalty on all properties advanced by Japan Gold Corp. from 1.5% to 2.0%. Royalty, stream and other interests grew to $1.49 billion at September 30, 2026 from $1.14 billion at year-end 2025, and the portfolio includes royalties and streams on 25 producing assets (including two assets that are expected to start generating revenues for the Company in 2027).

Portfolio Updates

Selected disclosures from operating partners’ third quarter of 2026 reporting, or other recent releases:

• Canadian Malartic Complex (Agnico Eagle Mines Limited (“Agnico Eagle”), October 28). Production of 111,202 ounces in Q3 2026. Remediation of the Barnat pit north wall was completed during the quarter and mining in unaffected areas of the pit resumed on September 27, 2026. Odyssey mined a record 391,000 tonnes in the quarter, East Gouldie produced 27,250 ounces of gold, and the first phase of shaft sinking was completed on July 9, 2026 at a depth of 1,586 metres, with shaft-hoisted production from East Gouldie planned for the second quarter of 2027. Agnico Eagle expects to submit a decree modification application for a second shaft in the first quarter of 2027 and will host a Capital Markets Day on November 18, 2026;
• Island Gold District (Alamos Gold Inc., October 28). Record quarterly production of 68,700 ounces of gold; underground mining rates averaged a record 1,790 tonnes per day, 35% higher than the prior-year period, and remain on track to reach 2,000 tonnes per day by the end of 2026. Shaft commissioning is now expected mid-2027;
• Lamaque (Eldorado Gold Corporation, October 28). Production of 52,748 ounces of gold, up 13% year-over-year, with Ormaque described as an increasingly important source of high-grade ore;
• Dalgaranga (Ramelius Resources Limited, October 26). Ramp-up continued with 214,000 tonnes processed at 3.47 grams per tonne (“g/t”) gold and 89% recovery, compared to 84% assumed in Ramelius’ four-year outlook; the Never Never underground mine is on track to mine 500,000 tonnes at 6.2 g/t gold in fiscal 2027;
• Mantos Blancos (Capstone Copper Corp., October 29). Capstone expects Mantos Blancos to trend towards the mid-point of its 2026 production guidance with higher copper grades in the fourth quarter; the Phase II expansion has been submitted to the Environmental Impact Assessment process;
• Hermosa (South32 Ltd., October 19). Both shafts are expected to reach the primary production level in the December 2026 quarter. In addition, on September 2, Hermosa achieved a significant permitting milestone with the completion of the U.S. federal permitting process under FAST-41, the first mining project ever completed under this expedited process;
• Costa Fuego and La Verde (Hot Chili Limited, October 30). A second porphyry discovery was confirmed at La Verde South, within the area added to the Company’s royalty coverage during the quarter; the maiden La Verde Mineral Resource Estimate and the revised Costa Fuego Pre-Feasibility Study remain on track for delivery in 2027, along with Environmental Permit submission for the updated Costa Fuego project;
• Upper Beaver (Agnico Eagle Mines Limited, October 28). Shaft sinking passed the halfway mark at 732 metres and the Environmental Impact Statement is expected to be submitted in the fourth quarter of 2026;
• Cariboo (Osisko Gold Group Inc., October 27). Construction approximately 28% complete and on schedule for first gold in the first quarter of 2029; and,
• Cuiú Cuiú (Cabral Gold Inc., September 10). Cabral expects to declare commercial production in the fourth quarter of 2026; first royalty payments to the Company are expected in the fourth quarter of 2026 or the first quarter of 2027.

Jason Attew, President and Chief Executive Officer, commented: “This is what the model looks like when it works. On essentially the same GEOs earned as in the third quarter last year, this year we generated 26% more revenue and 20% more operating cash flow, with a 96.8% cash margin converting higher gold prices almost entirely into cash. We also remain on track for approximately the mid-point of our 2026 guidance, even after absorbing the Barnat pit disruption at Canadian Malartic. More importantly, 2026 is the year our development pipeline turned into production: Dalgaranga, Cuiú Cuiú and Amulsar have all poured first gold in 2026, taking the portfolio to 25 producing assets. And with Windfall now holding its principal environmental approval and Cariboo already in construction, the two largest Canadian projects in our 2030 outlook have moved from permitting to execution. We could not be better placed to deliver on our peer-leading, fully-funded growth through the end of the decade.”

2026 Guidance

The Company reaffirms its 2026 guidance of 80,000 to 90,000 GEOs earned. With 63,734 GEOs earned through September 30, 2026, deliveries are tracking to approximately the mid-point of the range, after accounting for the reduced open-pit production at Canadian Malartic (Barnat pit) in the second half of 2026 disclosed by Agnico Eagle. The Company’s growth outlook through 2030 remains fully funded, with no contingent capital required.

Q3 2026 RESULTS CONFERENCE AND WEBCAST CALL DETAILS

Conference Call:	Thursday, November 12, 2026 at 10:00 am ET
Dial-in Numbers: (Option 1)	North American Toll-Free: 1 (800) 717-1738 Local – Montréal: 1 (514) 400-3792 Local – Toronto: 1 (289) 514-5100 Local – New York: 1 (646) 307-1865 Conference ID: 75234
Webcast link: (Option 2)	https://viavid.webcasts.com/starthere.jsp?ei=1777759&tp_key=f1a0b01c30
Replay (available until Saturday, December 12, 2026 at 11:59 pm ET):	North American Toll-Free: 1 (888) 660-6264 Local – Toronto: 1 (289) 819-1325 Local – New York: 1 (646) 517-3975 Playback Passcode: 75234#
	Replay also available on our website at www.ORroyalties.com

Qualified Person

The scientific and technical content of this news release has been reviewed and approved by Guy Desharnais, Ph.D., P.Geo., Vice President, Project Evaluation at OR Royalties Inc., who is a “qualified person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).

About OR Royalties Inc.

OR Royalties is a precious metals royalty and streaming company focused on Tier-1 mining jurisdictions defined as Canada, the United States, and Australia. OR Royalties commenced activities in June 2014 with a single producing asset, and today holds a portfolio of over 200 royalties, streams and similar interests. OR Royalties’ portfolio is anchored by its cornerstone asset, the 3–5% net smelter return royalty on Agnico Eagle Mines Limited’s Canadian Malartic Complex, one of the world’s largest gold mines.

OR Royalties’ head office is located at 1100 Avenue des Canadiens-de-Montréal, Suite 300, Montréal, Québec, H3B 2S2.

For further information, please contact OR Royalties Inc.:
Grant Moenting Vice President, Capital Markets Mobile: (365) 275-1954 Email: gmoenting@ORroyalties.com	Heather Taylor Vice President, Sustainability and Communications Tel: (647) 477-2087 Email: htaylor@ORroyalties.com

Notes:

(1)	Three months ended September 30, 2026 (“Q3 2026”) and three months ended September 30, 2025 (“Q3 2025”).
(2)	Gold Equivalent Ounces GEOs are calculated on a quarterly basis and include royalties and streams. Silver ounces and copper tonnes earned from royalty and stream agreements are converted to gold equivalent ounces by multiplying the silver ounces or copper tonnes earned by the average silver price per ounce or copper price per tonne for the period and dividing by the average gold price per ounce for the period. Cash royalties and other metals and commodities are converted into gold equivalent ounces by dividing the associated revenue earned by the average gold price for the period.

Average Metal Prices

	Three months ended September 30,							Nine months ended September 30,
		2026			2025				2026			2025
Gold (i)	$4,262			$3,457				$4,545			$3,201
Silver (ii)	$62.59			$39.40				$73.24			$35.05
Copper (iii)	$14,104			$9,797				$13,434			$9,556

	(i)	The London Bullion Market Association’s pm price in U.S. dollars per ounce.
	(ii)	The London Bullion Market Association’s price in U.S. dollars per ounce.
	(iii)	The London Metal Exchange’s price in U.S. dollars per tonne.

(3) Non-IFRS Measures

Cash Margin (in dollars and in percentage of revenues)

Cash margin in dollars and in percentage of revenues are non-IFRS financial measures. Cash margin (in dollars) is defined by OR Royalties as revenues less cost of sales (excluding depletion). Cash margin (in percentage of revenues) is obtained by dividing the cash margin (in dollars) by the revenues.

Management uses cash margin in dollars and in percentage of revenues to evaluate OR Royalties’ ability to generate positive cash flow from its royalty, stream and other interests. Management and certain investors also use this information, together with measures determined in accordance with IFRS Accounting Standards such as gross profit and operating cash flows, to evaluate OR Royalties’ performance relative to peers in the mining industry who present these measures on a similar basis. Cash margin in dollars and in percentage of revenues are only intended to provide additional information to investors and analysts and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS Accounting Standards. They do not have any standardized meaning under IFRS Accounting Standards and may not be comparable to similar measures presented by other issuers.

A reconciliation of the cash margin (in thousands of dollars and in percentage of revenues) is presented below:

	Three months ended September 30,						Nine months ended September 30,
	2026			2025			2026			2025
	$			$			$			$
Royalty interests
Revenues	55,964			42,734			181,140			121,709
Less: cost of sales (excluding depletion)	(371	)		(251	)		(1,100	)		(567	)
Cash margin (in dollars)	55,593			42,483			180,040			121,142
Depletion	(6,558	)		(2,697	)		(19,985	)		(8,815	)
Gross profit	49,035			39,786			160,055			112,327
Stream interests
Revenues	34,241			28,891			109,717			65,196
Less: cost of sales (excluding depletion)	(2,546	)		(2,116	)		(8,249	)		(5,979	)
Cash margin (in dollars)	31,695			26,775			101,468			59,217
Depletion	(5,527	)		(7,462	)		(15,263	)		(16,701	)
Gross profit	26,168			19,313			86,205			42,516
Royalty and stream interests Total cash margin (in dollars)	87,288			69,258			281,508			180,359
Divided by: total revenues	90,205			71,625			290,857			186,905
Cash margin (in percentage of revenues)	96.8	%		96.7	%		96.8	%		96.5	%
Total – Gross profit	75,203			59,099			246,260			154,843

Adjusted earnings and adjusted earnings per basic share

Adjusted earnings and adjusted earnings per basic share are non-IFRS financial measures and are defined by OR Royalties by excluding the following items from net earnings (loss) and net earnings (loss) per basic share: foreign exchange gains (losses), impairment charges and reversals related to royalty, stream and other interests, changes in allowance for expected credit losses, write-offs and impairments of investments, gains (losses) on disposal of royalty, stream and other interests (excluding gains (losses) on buy-down and buy-back of royalty, stream and other interests), gains (losses) on investments, share of income (loss) of associates, transaction costs and certain other items such as non-cash gains (losses), as well as the impact of income taxes on these items. Adjusted earnings per basic share is obtained from the adjusted earnings divided by the weighted average number of common shares outstanding for the period.

Management uses adjusted earnings and adjusted earnings per basic share to evaluate the underlying operating performance of OR Royalties as a whole for the reporting periods presented, to assist with the planning and forecasting of future operating results, and to supplement information in its consolidated financial statements. Management believes that in addition to measures prepared in accordance with IFRS Accounting Standards such as net earnings (loss) and net earnings (loss) per basic share, investors and analysts use adjusted earnings and adjusted earnings per basic share to evaluate the results of the underlying business of OR Royalties, particularly since the excluded items are typically not included in OR Royalties’ annual guidance. While the adjustments to net earnings (loss) and net earnings (loss) per basic share in these measures include items that are both recurring and non-recurring, management believes that adjusted earnings and adjusted earnings per basic share are useful measures of OR Royalties’ performance because they adjust for items which may not relate to or have a disproportionate effect on the period in which they are recognized, impact the comparability of the core operating results from period to period, are not always reflective of the underlying operating performance of the business and/or are not necessarily indicative of future operating results. Adjusted earnings and adjusted earnings per basic share are intended to provide additional information to investors and analysts and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS Accounting Standards. They do not have any standardized meaning under IFRS Accounting Standards and may not be comparable to similar measures presented by other issuers.

A reconciliation of net earnings to adjusted earnings is presented below:

	Three months ended September 30,						Nine months ended September 30,
	2026			2025			2026			2025
(in thousands of dollars, except per share amounts)	$			$			$			$
Net earnings	55,367			82,845			190,341			140,843
Adjustments:
Foreign exchange (gain) loss	(599	)		(300	)		2,757			(1,125	)
Share of loss of associates	–			8,313			–			14,178
Net (gain) loss on investments	(1,064	)		56			(3,907	)		366
Impairment of royalty, stream and other interests	–			5,495			–			5,495
Gain on deemed disposal of an associate	–			(54,439	)		–			(54,439	)
Reclassification of accumulated other comprehensive loss to the statement of income on the deemed disposal of an associate	–			1,147			–			1,147
Tax impact of adjustments	236			(850	)		273			(586	)
Adjusted earnings	53,940			42,267			189,464			105,879
Divided by: basic weighted average number of common shares outstanding (000’s)	186,641			188,312			187,268			187,685
Adjusted earnings per basic share	0.29			0.22			1.01			0.56

Net cash/(net debt) position (in dollars)

Net cash/(net debt) position is a non-IFRS financial measure and is defined by OR Royalties by the cash balance minus the long-term debt balance at the end of a period.

Management uses the net cash/(net debt) position to evaluate OR Royalties’ current net liquidity position (i.e. total cash less total long-term debt). Management and certain investors also use this information, together with measures determined in accordance with IFRS Accounting Standards such as operating cash flows and undrawn balances available under credit facilities, to evaluate OR Royalties’ investment capacity. Net cash/(net debt) position is only intended to provide additional information to investors and analysts and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS Accounting Standards. It does not have any standardized meaning under IFRS Accounting Standards and may not be comparable to similar measures presented by other issuers.

A reconciliation of the net cash/(net debt) position is presented below:

	September 30,		December 31,
	2026		2025
(in thousands of dollars)	$		$
Cash	76,718		142,131
Long-term debt	(228,189	)	–
Net (debt)/cash position	(151,471	)	142,131

Cash flows from operating activities per basic share

Cash flows from operating activities per basic share is a non-IFRS financial measure and is defined by OR Royalties as cash flows provided by operating activities divided by the basic weighted average number of common shares outstanding for the period.

Management uses cash flows from operating activities per basic share to evaluate OR Royalties’ ability to generate cash from its royalty, stream and other interests on a per share basis. Management and certain investors also use this information, together with measures determined in accordance with IFRS Accounting Standards such as cash flows provided by operating activities, to evaluate OR Royalties’ performance relative to peers in the mining industry who present this measure on a similar basis. Cash flows from operating activities per basic share is only intended to provide additional information to investors and analysts and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS Accounting Standards. It does not have any standardized meaning under IFRS Accounting Standards and may not be comparable to similar measures presented by other issuers.

A reconciliation of the cash flows from operating activities per basic share is presented below:

	Three months ended September 30,								Nine months ended September 30,
		2026				2025				2026				2025
(in thousands, except per share amounts)
Cash flows provided by operating activities	$77,564				$64,604				$232,596				$162,058
Divided by: basic weighted average number of common shares outstanding (000’s)		186,641				188,312				187,268				187,685
Cash flows from operating activities per basic share	$0.42				$0.34				$1.24				$0.86

(4)	Includes all available cash on the Company’s balance sheet ($76.7 million), as well as any undrawn amount(s) available on the Company’s revolving credit facility ($621.8 million) plus the accordion ($350.0 million), which is uncommitted and subject to acceptance by the lenders, all as at September 30, 2026.
(5)	Q3 2025 included a non-recurring gain of $54.4 million on deemed disposal of an associate.

Forward-Looking Statements

Certain statements contained in this press release may be deemed “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking statements are statements other than statements of historical fact, that address, without limitation, future events, that the 2026 guidance on GEOs will be achieved, that the buy back option by SolGold Finance AG will be made in a timely manner, that the deferred payments will be timely made by Galiano Gold Inc., that development and milestones and ramping up to be achieved by operators of the properties in which the Company holds interest will be achieved in a timely manner, that cash inflows of $65 million will be achieved in the fourth quarter, and the ability of the Company to continue to invest in new opportunities. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential”, “scheduled” and similar expressions or variations (including negative variations), or that events or conditions “will”, “would”, “may”, “could” or “should” occur. All statements in this press release, other than statements of historical fact, are forward-looking statements, including statements that address, without limitation: future events. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors, most of which are beyond the control of OR Royalties, and actual results may accordingly differ materially from those in forward-looking statements. Such risk factors include, without limitation, (i) with respect to properties in which OR Royalties holds a royalty, stream or other interest; risks related to: (a) the operators of the properties, (b) timely development, permitting, construction, commencement of production, ramp-up (including operating and technical challenges), (c) differences in rate and timing of production from Mineral Resource Estimates or production forecasts by operators, (d) differences in conversion rate from Mineral Resources to Mineral Reserves and ability to replace Mineral Resources, (e) the unfavorable outcome of any challenges or litigation relating to title, permit or license, (f) hazards and uncertainty associated with the business of exploring, development and mining including, but not limited to unusual or unexpected geological and metallurgical conditions, slope failures or cave-ins, flooding and other natural disasters or civil unrest or other uninsured risks, (ii) with respect to other external factors: (a) fluctuations in the prices of the commodities that drive royalties, streams, offtakes and investments held by OR Royalties, (b) a trade war or new tariff barriers, (c) fluctuations in the value of the Canadian dollar relative to the U.S. dollar, (d) regulatory changes by national and local governments, including permitting and licensing regimes and taxation policies, regulations and political or economic developments in any of the countries where properties in which OR Royalties holds a royalty, stream or other interest are located or through which they are held, (e) continued availability of capital and financing and general economic, market or business conditions, (f) responses of relevant governments to infectious diseases outbreaks and the effectiveness of such response and the potential impact of such outbreaks on OR Royalties’ business, operations and financial condition, and (g) geopolitical uncertainties; (iii) with respect to internal factors: (a) business opportunities that may or may not become available to, or are pursued by OR Royalties, (b) the integration of acquired assets, (c) the determination of OR Royalties’ PFIC status or (d) that preliminary financial information may be subject to quarter-end and year-end adjustments. The forward-looking statements contained in this press release are based upon assumptions management believes to be reasonable, including, without limitation: the absence of significant change in OR Royalties’ ongoing income and assets relating to determination of its PFIC status, and the absence of any other factors that could cause actions, events or results to differ from those anticipated, estimated or intended and, with respect to properties in which OR Royalties holds a royalty, stream or other interest, (i) the ongoing operation of the properties by the owners or operators of such properties in a manner consistent with past practice and with public disclosure (including forecast of production), (ii) the accuracy of public statements and disclosures made by the owners or operators of such underlying properties (including expectations for the development of underlying properties that are not yet in production), (iii) no adverse development in respect of any significant property, (iv) that statements and estimates relating to mineral reserves and resources by owners and operators are accurate and (v) the implementation of an adequate plan for integration of acquired assets.

For additional information on risks, uncertainties and assumptions, please refer to the most recent Annual Information Form of OR Royalties filed on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov which also provides additional general assumptions in connection with these statements. OR Royalties cautions that the foregoing list of risks and uncertainties is not exhaustive. Investors and others should carefully consider the above factors as well as the uncertainties they represent and the risk they entail. OR Royalties believes that the assumptions reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be accurate as actual results and prospective events could materially differ from those anticipated in such forward-looking statements, and such forward-looking statements included in this press release are not a guarantee of future performance and should not be unduly relied upon. These statements speak only as of the date of this press release. OR Royalties undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by applicable law.

OR Royalties Inc. Consolidated Balance Sheets As at September 30, 2026 and December 31, 2025 (Unaudited)
(tabular amounts expressed in thousands of U.S. dollars)
	September 30,			December 31,
	2026			2025
	$			$
Assets
Current assets
Cash	76,718			142,131
Amounts receivable	2,160			3,227
Deferred consideration receivable	30,000			–
Other assets	881			2,326
	109,759			147,684
Non-current assets
Investments	204,088			189,260
Royalty, stream and other interests	1,489,407			1,140,026
Goodwill	78,376			81,134
Other assets	9,751			8,375
	1,891,381			1,566,479
Liabilities
Current liabilities
Accounts payable and accrued liabilities	6,003			7,477
Dividends payable	12,114			10,293
Income tax liabilities	14,996			13,655
Lease liabilities	1,236			1,207
	34,349			32,632
Non-current liabilities
Lease liabilities	2,752			3,795
Long-term debt	228,189			–
Deferred income taxes	107,891			98,011
	373,181			134,438
Equity
Share capital	1,687,558			1,688,122
Contributed surplus	61,447			65,873
Accumulated other comprehensive loss	(97,646	)		(51,780	)
Deficit	(133,159	)		(270,174	)
	1,518,200			1,432,041
	1,891,381			1,566,479

OR Royalties Inc. Consolidated Statements of Income For the three and nine months ended September 30, 2026 and 2025 (Unaudited)
(tabular amounts expressed in thousands of U.S. dollars, except per share amounts)
	Three months ended September 30,						Nine months ended September 30,
	2026			2025			2026			2025
	$			$			$			$
Revenues	90,205			71,625			290,857			186,905
Cost of sales	(2,917	)		(2,367	)		(9,349	)		(6,546	)
Depletion	(12,085	)		(10,159	)		(35,248	)		(25,516	)
Gross profit	75,203			59,099			246,260			154,843
Other operating expenses
General and administrative	(4,534	)		(4,902	)		(15,503	)		(15,799	)
Business development	(3,100	)		(2,015	)		(7,624	)		(6,920	)
Impairment of royalty, stream and other interests	–			(5,495	)		–			(5,495	)
Gain on the buy-down of a stream interest	–			–			7,161			–
Gain on sale of gold bullion	–			–			419			–
Operating income	67,569			46,687			230,713			126,629
Interest income	1,365			1,062			4,810			2,278
Finance costs	(3,621	)		(886	)		(7,598	)		(3,740	)
Foreign exchange gain (loss)	599			300			(2,757	)		1,125
Share of loss of associates	–			(8,313	)		–			(14,178	)
Other gains, net	1,064			53,236			3,907			52,926
Earnings before income taxes	66,976			92,086			229,075			165,040
Income tax expense	(11,609	)		(9,241	)		(38,734	)		(24,197	)
Net earnings	55,367			82,845			190,341			140,843
Net earnings per share
Basic	0.30			0.44			1.02			0.75
Diluted	0.30			0.44			1.01			0.74

OR Royalties Inc. Consolidated Statements of Cash Flows For the three and nine months ended September 30, 2026 and 2025 (Unaudited)
(tabular amounts expressed in thousands of U.S. dollars)
	Three months ended September 30,						Nine months ended September 30,
	2026			2025			2026			2025
	$			$			$			$
Operating activities
Net earnings	55,367			82,845			190,341			140,843
Adjustments for:
Share-based compensation	1,850			2,056			5,533			6,316
Depletion and amortization	12,422			10,493			36,260			26,434
Impairment of royalty, stream and other interests	–			5,495			–			5,495
Gain on the buy-down of a stream interest	–			–			(7,161	)		–
Gain on sale of gold bullion	–			–			(419	)		–
Share of loss of associates	–			8,313			–			14,178
Gain on shares received under an anti-dilution provision	–			–			(794	)		–
Change in fair value of financial assets at fair value through profit and loss	(1,064	)		56			(3,131	)		366
Gain on deemed disposal of an associate	–			(54,439	)		–			(54,439	)
Reclassification to the statement of income of other comprehensive loss on the deemed disposal of an investment in associate	–			1,147			–			1,147
Foreign exchange (gain) loss	(317	)		(291	)		2,984			(1,170	)
Deferred income tax expense	2,556			5,598			8,634			13,905
Other	(615	)		(74	)		(1,691	)		196
Net cash flows provided by operating activities before changes in non-cash working capital items	70,199			61,199			230,556			153,271
Changes in non-cash working capital items	7,365			3,405			2,040			8,787
Net cash flows provided by operating activities	77,564			64,604			232,596			162,058
Investing activities
Acquisitions of deferred payment obligations	–			–			(52,000	)		–
Acquisitions of investments	(7,420	)		–			(17,420	)		(12,359	)
Proceeds on disposal of investments	–			805			34,748			805
Acquisitions of royalty and stream interests	(40,208	)		(13,655	)		(421,642	)		(36,869	)
Proceeds from the sale of gold bullion	–			–			17,875			–
Proceeds on the exercise of a buy-down right	–			2,051			–			2,051
Other	(57	)		(371	)		(134	)		(844	)
Net cash flows used in investing activities	(47,685	)		(11,170	)		(438,573	)		(47,216	)
Financing activities
Increase in long-term debt	28,496			–			277,496			10,437
Repayment of long-term debt	(15,000	)		(35,372	)		(49,000	)		(105,372	)
Exercise of share options and shares issued under the share purchase plan	250			38			4,772			11,514
Normal course issuer bid purchase of common shares	(29,094	)		–			(50,016	)		–
Dividends paid	(11,328	)		(9,700	)		(30,514	)		(25,163	)
Withholding taxes on settlement of restricted and deferred share units	(271	)		–			(10,102	)		(6,464	)
Other	(1,565	)		(361	)		(2,158	)		(1,836	)
Net cash flows (used in) provided by financing activities	(28,512	)		(45,395	)		140,478			(116,884	)
Increase (decrease) in cash before effects of exchange rate changes on cash	1,367			8,039			(65,499	)		(2,042	)
Effects of exchange rate changes on cash	(254	)		(623	)		86			(12	)
Net increase (decrease) in cash	1,113			7,416			(65,413	)		(2,054	)
Cash – beginning of period	75,605			49,626			142,131			59,096
Cash – end of period	76,718			57,042			76,718			57,042

• Q3 revenue totals $21.6 million
• Q3 net income and adjusted EBITDA of $1.2 million and $6.3 million
• 2026 revenue guidance updated to $87-$93 million; adjusted EBITDA guidance unchanged at $21-$25 million
• Repaid $9.3 million in debt principal since June 30, 2026, reducing current outstanding principal to $10.4 million

WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended September 30, 2026.

Financial Highlights

• Revenue decreased 17% to $21.6 million in Q3 2026, compared to $26.1 million in Q3 2025.
• GAAP net income of $1.2 million or $0.06 per basic and diluted share in Q3 2026, compared to GAAP net income of $0.8 million, or $0.04 per basic and diluted share, in Q3 2025.
• Non-GAAP net income of $3.8 million, or $0.20 per diluted share in Q3 2026, compared to Non-GAAP net income of $3.1 million or $0.16 per diluted share, in Q3 2025. (See *Non-GAAP Measures below)
• Adjusted EBITDA of $6.3 million in Q3 2026 compared to $5.1 million in Q3 2025. (See *Non-GAAP Measures below)
• Operating cash flow was $12.9 million for the nine months ended September 30, 2026 and the Company had cash and cash equivalents of $22.3 million as of September 30, 2026 compared to $23.4 million as of December 31, 2025.

Stephen L. Silvestro, OptimizeRx CEO commented, “Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.

“While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season. We are seeing expanding opportunities within key accounts, renewed spending in the fourth quarter from a previously significant customer, and indications of pent-up demand as customers execute against their marketing budgets for the 2027 RFP season. We believe these developments, along with our continued focus on strengthening our commercial leadership and broadening our product capabilities, position us to capture additional demand and support future growth.

“More importantly, we believe OptimizeRx is uniquely positioned for the next evolution of healthcare marketing through three fundamental competitive advantages: our proven and increasingly scalable artificial intelligence (AI)-enabled platform, our proprietary healthcare data and solutions that are difficult to replicate or disintermediate, and our deeply integrated EHR network with substantial reach and meaningful barriers to entry. Our Dynamic Audience Activation Platform and expanding AI-enabled audience intelligence capabilities demonstrate the value of these investments, while our partnerships with DeepIntent, The Trade Desk, and PulsePoint are broadening programmatic access to our proprietary network. Together, these initiatives create opportunities to increase network utilization, expand customer reach, and capture a greater share of pharmaceutical marketing budgets. We believe the progress we’ve made throughout 2026 has established a stronger foundation for sustainable, profitable growth and long-term shareholder value creation.”

	Rolling Twelve Months Ended September 30,
Key Performance Indicators (KPIs)**		2026				2025
	(in thousands, except percentages)
Average revenue per top 20 pharmaceutical manufacturer	$	2,504			$	3,087
Percent of total revenue attributable to top 20 pharmaceutical manufacturers		53	%			56	%
Net revenue retention		83	%			121	%
Revenue per average full-time employee	$	706			$	820

2026 Financial Outlook

The Company is updating its fiscal year 2026 guidance, and now expects revenue of $87 million to $93 million and adjusted EBITDA of $21 million to $25 million.

Conference Call

Date:	Wednesday, November 11, 2026
Time:	4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Toll Free:	1-877-407-9716
International:	1-201-493-6779
Conference ID:	13763502
Call Me:	https://callme.viavid.com/viavid/?callme=true&passcode=13760191&h=true&info=company-email&r=true&B=6
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1780405&tp_key=07d90b8ba4
Webcast Replay:	The archived webcast will be on the investor relations section of the OptimizeRx website.

Individual Meeting Invitation

As part of our ongoing investor outreach efforts, OptimizeRx management has dedicated time to hosting individual meetings with portfolio managers and analysts. If you are interested in scheduling a meeting with OptimizeRx management, please contact: adsilva@optimizerx.com or dfarrell@lifesciadvisors.com.

*Non-GAAP Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors and, for historical periods, a reconciliation of these measures to the most directly comparable GAAP measures are included in the supplemental tables that follow.

Although the Company provides guidance for adjusted EBITDA, a non-GAAP financial measure, it is not able to provide guidance to the most directly comparable GAAP measure. Reconciliations for forward-looking figures would require unreasonable effort at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, other income, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

**Definition of Key Performance Indicators

Top 20 pharmaceutical manufacturers: We have updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2025 revenue”. We previously used “The top 20 pharma companies by 2024 revenue”. As a result of this change, prior periods have been restated for comparative purposes.

Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous 12 months period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

Revenue per average full-time employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by averaging our total number of FTEs at the end of the prior year period and our total FTE headcount at the end of the most recent period.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and direct-to-consumer (DTC) strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com. 

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s future performance, expected revenues, expected adjusted EBITDA, the Company’s updated fiscal year 2026 guidance, expected trends in contracted revenue, expanding opportunities within key accounts, renewed customer spending, current strength in the RFP season resulting in growth in contracted revenue, anticipated demand in connection with the 2027 RFP season resulting in customers executing against their marketing budgets, the Company’s investments in commercial leadership and expanded product capabilities positioning the Company to capture additional demand and support future growth, the Company’s competitive advantages, including its AI-enabled platform, proprietary healthcare data and solutions, and integrated EHR network, the DAAP and AI-enabled audience intelligence capabilities, the Company’s partnerships with DeepIntent, The Trade Desk, and PulsePoint broadening programmatic access to the Company’s network, opportunities to increase network utilization, expand customer reach, and capture a greater share of pharmaceutical marketing budgets, the Company’s foundation for sustainable, profitable growth, and long-term shareholder value creation, and other statements relating to future performance, plans, and expectations. These forward-looking statements are based on the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, changes in the timing, amount or renewal of customer contracts and marketing budgets, the ability to successfully develop, commercialize and achieve market acceptance of AI-enabled products and solutions, reliance on third-party partners, including programmatic advertising partners, the Company’s indebtedness, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, its subsequent Quarterly Reports on Form 10-Q, and in other filings the Company has made and may make with the Securities and Exchange Commission in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact
Andy D’Silva, Chief Business Officer
adsilva@optimizerx.com

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
dfarrell@lifesciadvisors.com

OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)
	September 30, 2026				December 31, 2025
ASSETS	(unaudited)
Current assets
Cash and cash equivalents	$	22,325			$	23,365
Accounts receivable, net of allowance for credit losses of $295 and $260 at September 30, 2026 and December 31, 2025, respectively		25,175				37,752
Taxes receivable		1,653				752
Prepaid expenses and other		3,877				2,846
Total current assets		53,030				64,715
Property and equipment, net		115				106
Other assets
Goodwill		70,869				70,869
Patent rights, net		4,107				4,586
Technology assets, net		5,987				6,870
Customer relationships, net		27,570				29,340
Operating lease right of use assets		397				404
Security deposits and other assets		18				28
Total other assets		108,948				112,097
TOTAL ASSETS	$	162,093			$	176,918
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Current portion of long-term debt	$	1,250			$	4,255
Accounts payable		1,838				1,636
Accrued expenses		5,108				11,591
Revenue share payable		1,552				3,086
Current portion of lease liabilities		232				193
Deferred revenue		502				503
Total current liabilities		10,482				21,264
Non-current liabilities
Long-term debt, net		11,479				21,421
Lease liabilities, net of current portion		185				234
Deferred tax liabilities, net		6,069				5,705
Total liabilities		28,215				48,624
Commitments and contingent liabilities
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at September 30, 2026 or December 31, 2025		—				—
Common stock, $0.001 par value, 166,666,667 shares authorized, 20,648,099 and 20,500,986 shares issued at September 30, 2026 and December 31, 2025, respectively		21				20
Treasury stock, $0.001 par value, 1,741,397 shares held at September 30, 2026 and December 31, 2025		(2	)			(2	)
Additional paid-in-capital		213,083				207,512
Accumulated other comprehensive income		15				—
Accumulated deficit		(79,239	)			(79,236	)
Total stockholders’ equity		133,878				128,294
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	162,093			$	176,918

OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (in thousands, except share and per share data, unaudited)
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Net revenue	$	21,615			$	26,067			$	61,963			$	77,190
Expenses
Cost of revenues, exclusive of depreciation and amortization presented separately below		5,369				8,551				15,097				27,695
Sales and marketing		4,399				5,517				14,656				16,367
General and administrative		3,400				4,169				10,615				12,635
Research and development		2,929				2,723				9,605				9,067
Stock-based compensation		1,784				1,956				5,820				5,002
Depreciation and amortization		1,064				1,080				3,192				3,249
Total expenses		18,945				23,996				58,985				74,015
Income from operations		2,670				2,071				2,978				3,175
Other income (expense)
Interest expense		(177	)			(1,154	)			(2,459	)			(4,053	)
Other income		11				62				87				139
Interest income		62				91				220				269
Total other expenses, net		(104	)			(1,001	)			(2,152	)			(3,645	)
Income (loss) before provision for income taxes		2,566				1,070				826				(470	)
Income tax (expense) benefit		(1,371	)			(291	)			(829	)			582
Net income (loss)	$	1,195			$	779			$	(3	)		$	112
Other comprehensive income, net of tax:
Foreign currency translation adjustment		4				—				15				—
Comprehensive income	$	1,199			$	779			$	12			$	112
Weighted average number of shares outstanding – basic		18,866,127				18,576,199				18,804,756				18,519,665
Weighted average number of shares outstanding – diluted		19,221,763				19,459,877				18,804,756				19,021,905
Income (loss) per share – basic	$	0.06			$	0.04			$	—			$	0.01
Income (loss) per share – diluted	$	0.06			$	0.04			$	—			$	0.01

OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, unaudited)
	For the Nine Months Ended September 30,
		2026				2025
OPERATING ACTIVITIES:
Net (loss) income	$	(3	)		$	112
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization		3,192				3,249
Stock-based compensation		5,820				5,002
Bad debt expense		42				—
Amortization of debt issuance costs		670				785
Changes in:
Accounts receivable		12,535				5,985
Prepaid expenses and other assets		(1,031	)			(448	)
Accounts payable		202				(119	)
Revenue share payable		(1,534	)			(2,724	)
Accrued expenses and other liabilities		(6,472	)			1,913
Operating lease liabilities		(3	)			15
Deferred tax liabilities		364				—
Taxes receivable and payable		(901	)			(2,065	)
Deferred revenue		(1	)			(78	)
NET CASH PROVIDED BY OPERATING ACTIVITIES		12,880				11,627
INVESTING ACTIVITIES:
Purchases of property and equipment		(68	)			(47	)
Capitalized software development costs		—				(91	)
NET CASH USED IN INVESTING ACTIVITIES		(68	)			(138	)
FINANCING ACTIVITIES:
Cash paid for employee withholding taxes related to the vesting of restricted stock units		(271	)			(188	)
Proceeds from exercise of stock options		21				338
Proceeds from term loan, net of issuance costs		24,298				—
Repayment of long-term debt		(37,915	)			(5,500	)
NET CASH USED IN FINANCING ACTIVITIES		(13,867	)			(5,350	)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		15				—
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(1,040	)			6,139
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD		23,365				13,380
CASH AND CASH EQUIVALENTS – END OF PERIOD	$	22,325			$	19,519
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	1,805			$	6,677
Cash paid for income taxes	$	1,375			$	2,094

OPTIMIZERX CORPORATION
RECONCILIATION of GAAP to NON-GAAP FINANCIAL MEASURES
(in thousands, except share and per share data, unaudited)

This earnings release includes certain financial measures that are not prepared in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures are performance measures that are not defined under GAAP and should be considered in addition to, and not as a substitute for, the most directly comparable GAAP measures. They may also not be comparable to similarly titled measures reported by other companies. Management believes that presenting these non-GAAP financial measures provides useful supplemental information that facilitates comparison of the Company’s historical operating results and trends, and offers transparency into how management evaluates the business. Management uses these measures in making financial, operating and planning decisions and in evaluating the Company’s performance. Excluding items that management does not consider reflective of ongoing operating results improves the comparability of year-over-year results and helps investors better understand the Company’s underlying performance. These adjustments may include items such as asset impairment charges, amortization, stock-based compensation, acquisition expenses, severance related to executive departures and reductions in force initiatives, shareholder activist related fees, CEO search fees, CMO search fees, other income, estimated income tax impact from adjustments and other items that management believes are not related to the Company’s ongoing performance.

RECONCILIATION of GAAP NET INCOME (LOSS) to NON-GAAP NET INCOME
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Net income (loss)	$	1,195			$	779			$	(3	)		$	112
Depreciation and amortization		1,064				1,080				3,192				3,249
Stock-based compensation		1,784				1,956				5,820				5,002
Severance expenses		697				—				2,441				275
Shareholder activist related fees		—				—				—				451
CEO search fees		—				—				—				225
CMO search fees		80				—				120				—
Other income		(11	)			(62	)			(87	)			(139	)
Amortization of debt issuance costs		35				174				670				785
Estimated income tax impact from adjustments*		(1,009	)			(871	)			(3,362	)			(2,724	)
Non-GAAP net income	$	3,835			$	3,056			$	8,791			$	7,236
Non-GAAP net income per share
Diluted	$	0.20			$	0.16			$	0.46			$	0.38
Weighted average shares outstanding:
Diluted		19,221,763				19,459,877				19,074,626				19,021,905
*Estimated income tax impact from adjustments – consists of current and deferred income tax expense commensurate with the level of adjusted income before income taxes and utilizes an estimated current, blended U.S. and state statutory annual tax rate of 27.6% for all fiscal periods of fiscal 2026 and fiscal 2025. This rate may be subject to change in the future, including as a result of changes in tax policy or tax strategy.

RECONCILIATION of GAAP NET INCOME (LOSS) to ADJUSTED EBITDA
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Net income (loss)	$	1,195			$	779			$	(3	)		$	112
Depreciation and amortization		1,064				1,080				3,192				3,249
Income tax expense (benefit)		1,371				291				829				(582	)
Stock-based compensation		1,784				1,956				5,820				5,002
Severance expenses		697				—				2,441				275
Shareholder activist related fees		—				—				—				451
CEO search fees		—				—				—				225
CMO search fees		80				—				120				—
Other income		(11	)			(62	)			(87	)			(139	)
Interest expense, net		115				1,063				2,239				3,784
Adjusted EBITDA	$	6,295			$	5,107			$	14,551			$	12,377